Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Discovery Laboratories — Corporate Update (November 2015)

33 slides from Windtree Therapeutics's corporate update, Nov 12, 2015

  1. Slide 1: AEROSURF Phase 2 Program Update Investor Conference Call

    AEROSURF® Phase 2 Program UpdateInvestor Conference CallNovember 12, 2015

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Compan

  3. Slide 3: Respiratory Distress Syndrome (RDS)

    Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange – O2 in and CO2 out)American Academy of Pediatrics guidelines recommend providing surfactant replacement within

  4. Slide 4: Aerosolized Surfactant for RDS

    Aerosolized Surfactant for RDS Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human lung surfactantSURFAXIN® - Liquid KL4 surfactant (intratracheal instillate) for RDS approved by the FDA Innovative Aerosol Delivery Technology Designed specifically for the capability to

  5. Slide 5: Current Treatment of RDS: Intubate or Not?

    Current Treatment of RDS: Intubate or Not? Surfactant replacement therapy (SRT) - requires intubation and mechanical ventilation (MV); available surfactants are animal-derivedInvasive intubation and MV can result in serious respiratory conditions and other complications, such as higher risk of infec

  6. Slide 6: Current Treatment of RDS: nCPAP Used Across All Gestational Ages and Severity

    Current Treatment of RDS: nCPAP Used Across All Gestational Ages and Severity of RDS Frequency of RDS HIGHER LOWER Severe Moderate Mild GA <26 wks(>95% RDS) GA 26-28 wks(85-95% RDS) GA 29-32 wks(65-75% RDS) GA 33-34 wks(40-50% RDS) GA 35-36 wks(5-15% RDS) 20% ETT/SRT CPAP 80% 30% ETT/SRT CPAP 70% 55

  7. Slide 7: Trends in Non-Invasive Care of Neonates

    Current Treatment of RDS: Trends in Non-Invasive Care of Neonates – Increasing Use of nCPAP to Avoid Intubation However, still experience high nCPAP failure rates First-line nCPAP use has been trending up across all gestational ages up to 32 weeks GA Est. GA: < 24 wks ~24-27 wks ~28-29 wks ~30-32 wk

  8. Slide 8: Clinicians seeking a non-invasive way to deliver SRT

    RDS: Clinicians seeking a non-invasive way to deliver SRT What is wanted1:An approach that effectively delivers surfactant without intubation or mechanical ventilationPossibility of repeat dosesAvoids clinical instability associated with bolus administrationAdministration by non-specialist staffRedu

  9. Slide 9: Potential to Transform Management of RDS

    Potential to Transform Management of RDS Capillary Drug pumped through capillary Energy Input Aerosolized KL4 Surfactant via nCPAP Goal is to administer surfactant without invasive intubation and early in the management of RDS in premature infants ® We are conducting the AEROSURF® development progra

  10. Slide 10: Bridge the Surfactant / RDS Gap in the First Hours to 72 Hours

    Bridge the Surfactant / RDS Gap in the First 72 Hours 48 to 72 Hours Surfactant Deficient Endogenous Surfactant Production Birth ® GoalProvide surfactant therapy to premature infants until they can produce their own endogenous surfactantAllow for single or repeat non-invasive doses of aerosolized su

  11. Slide 11: Comprehensive Phase 2 Program

    Comprehensive Phase 2 Program Phase 2a Phase 2a Expansion Phase 2a Phase 2b Gestational Age (wks) 29 – 34 26 - 28 26 – 32(Begin with 29 – 32) Dose Groups 15 min; 30 min; 45 min( 25, 50, 75 TPL mg/kg)(8 active, 8 control per group)Single dose 60 min; 90 min (100 and 150 TPL mg/kg)(8 active, 8 control

  12. Slide 12: Clinical Program (29 to 34 weeks GA) Top-Line Data Review

    Phase 2a Clinical Program (29 to 34 weeks GA)Top-Line Data Review ®

  13. Slide 13: Study Design

    Phase 2a Study (29 to 34 wks GA)Study Design Evaluate the safety and tolerability of aerosolized KL4 surfactant (lucinactant 30 mg TPL/ml) for inhalation, administered to preterm neonates 29 to 34 weeks post-menstrual age (PMA) receiving nCPAP for RDS, compared to neonates receiving nCPAP alone.Desi

  14. Slide 14: Study Design (cont'd): Inclusion and Exclusion Criteria

    Inclusion CriteriaGestational age 29 to 34 weeks PMAImplementation of controlled nCPAP within 60 minutes after birthSpontaneous breathingChest radiograph consistent with RDSWithin the first 21 hours after birth, requires the following to maintain SpO2 of 88% - 95%nCPAP of 5 to 6 cm H2OFiO2 of 0.30 t

  15. Slide 15: Study Objectives

    Phase 2a Study (29 to 34 wks GA)Study Objectives Primary ObjectiveSafety and tolerability of AEROSURF® compared to nCPAP aloneOther Key ObjectivesAssess physiological data indicating that aerosolized KL4 surfactant is being delivered into the lungs of premature infantsGas exchange: FiO2 requirements

  16. Slide 16: Safety & Tolerability - Administration & Peri-Dosing

    Phase 2a Study (29 to 34 wks GA)Safety & Tolerability – Administration & Peri-Dosing The nasal interface and nasal prongs were well tolerated Upper airway obstruction was not observed 16 Complications of patient interface All AEROSURF (N=40) Bleeding 0 Apparent obstruction of the nares 0 Bi-nasal pr

  17. Slide 17: Safety & Tolerability - Adverse Events

    Phase 2a Study (29 to 34 wks GA)Safety & Tolerability - Adverse Events Co-morbidities and adverse events occur frequently in this patient population Adverse Event Observations:The most common adverse events in the AEROSURF® and control groups were:Neonatal jaundice ConstipationApnea AnemiaAll observ

  18. Slide 18: Adverse Events - Incidence of Air Leak

    Phase 2a Study (29 to 34 wks GA) Adverse Events - Incidence of Air Leak 18 Types of Air Leak Control(N=40) AEROSURF®(N=40) Pneumothorax/Pneumomediastinum 5 (13%)1 9 (23%)2, 3 Pulmonary Interstitial Emphysema 2 (5%) 1 (3%) Total Number of Infants4 7 (18%) 9 (23%) 1 Includes 4 patients with an SAE and

  19. Slide 19: Safety & Tolerability - Serious Adverse Events (SAE)

    Phase 2a Study (29 to 34 wks GA)Safety & Tolerability - Serious Adverse Events (SAE) 19 SAE Control(N=40) AEROSURF®(N=40) Apnea 0 1 (3%) Oxygen saturation decreased 0 1 (3%) Necrotising enterocolitis 1 (3%) 2 (5%) Cardio-respiratory arrest 1 (3%) 1 (3%)1 Hydrocephalus 1 (3%) 0 Pneumothorax/Pneumomed

  20. Slide 20: Safety and Tolerability - Summary

    Phase 2a Study (29 to 34 wks GA)Safety and Tolerability - Summary The adverse events seen in this trial were expected for this patient population The adverse events and complications of prematurity were generally comparable between AEROSURF® and control groupsThere was no pattern of increased advers

  21. Slide 21: nCPAP Failure by Treatment Group

    Phase 2a Study (29 to 34 wks GA)nCPAP Failure by Treatment Group through 72 hours 21 * One intubated patient excluded due to being inappropriately enrolled 2/7* 3/8 3/8 21/40 5/8 6/8 ® AEROSURF treatment, primarily in single doses of 45 minutes and greater, appears to be associated with lower rates

  22. Slide 22: Patients on Room Air at 1 Hour Post Start of Treatment

    AEROSURF® Phase 2a Study (29 to 34 wks GA) Patients on Room Air at 1 Hour Post Start of Treatment1 % of Subjects on Room Air at 1 Hour After Dosing 22 1 For control patients time is 1 hour after randomization At 1 hour after start of treatment, 28% of all AEROSURF® patients were at 21% O2 (room air)

  23. Slide 23: Gas Exchange - Change in FiO2 and CO2

    23 Phase 2a Study (29 to 34 wks GA)Gas Exchange – Change in FiO2 and CO2 (at 3 hrs) ® The data suggest that AEROSURF is associated with a decrease in FiO2 shortly after initiation of treatment and numerically greater change in PCO2 levels compared to control, suggesting that aerosolized KL4 surfacta

  24. Slide 24: Bridge the Surfactant / RDS Gap in the First Hours to 72 Hours

    Bridge the Surfactant / RDS Gap in the First 72 Hours 48 to 72 Hours Surfactant Deficient Endogenous Surfactant Production Birth ® GoalProvide surfactant therapy to premature infants until they can produce their own endogenous surfactantAllow for single or repeat non-invasive doses of aerosolized su

  25. Slide 25: Time to Intubation for nCPAP Failure for Control Group

    Phase 2a Study (29 to 34 wks GA) Time to Intubation for nCPAP Failure for Control Group ® 25 nCPAP failures due to RDS normally occur within 72 hours; in the control group (n=40) majority of nCPAP failures occurred within 48 hours of life

  26. Slide 26: Time to Intubation for nCPAP Failure by Treatment Group

    Phase 2a Study (29 to 34 wks GA) Time to Intubation for nCPAP Failure by Treatment Group ® 26 AEROSURF may prolong the time to intubation; repeat dosing may be important to extend this effect to surfactant self-sufficiency Control Dose Groups 3,4 & 5 Dose Groups 1 & 2 (15 & 30 min) (45, 60 & 90 min)

  27. Slide 27: nCPAP Failure by Treatment Group

    Phase 2a Study (29 to 34 wks GA)nCPAP Failure by Treatment Group through 72 hours 27 * One intubated patient excluded due to being inappropriately enrolled 2/7* 3/8 3/8 21/40 5/8 6/8 ® AEROSURF treatment, primarily in single doses of 45 minutes and greater, appears to be associated with lower rates

  28. Slide 28: 45 and 60 Minute Dose Groups - nCPAP Failure

    Phase 2a Study (29 to 34 wks GA)45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours No AEROSURF patients in the 45 and 60 minute dose groups required intubation at 3 or 6 hours post-dosing compared to 18% (7/40) of control patientsAEROSURF 45 and 60 minute doses may be reducing the rates o

  29. Slide 29: 45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours

    Phase 2a Study (29 to 34 wks GA) 45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours 21/40 5/15* ® Time to nCPAP Failure 29 nCPAP Failure AEROSURF treated patients experienced a 20% absolute reduction or a 38% relative reduction in nCPAP failure compared to control (45 & 60 min) (45 & 60 m

  30. Slide 30: Moving Forward - Window for Repeat Dosing

    Phase 2a Study (29 to 34 wks GA)Moving Forward – Window for Repeat Dosing ® 30 Potential repeat dose nCPAP Failure through 72 hours Additional dose if needed 45 and 60 minute Dose Groups * One intubated patient excluded due to being inappropriately enrolled

  31. Slide 31: Summary to Date

    Phase 2a Study (29 to 34 wks GA) Summary to Date Overall, the safety and tolerability profile of the AEROSURF group in the trial was generally comparable to the control group There was acceptable performance by the novel aerosol delivery technology in the NICUAerosolized surfactant produces physiolo

  32. Slide 32: Comprehensive Phase 2 Program

    Comprehensive Phase 2 Program Phase 2a Phase 2a Expansion Phase 2a Phase 2b Gestational Age (wks) 29 – 34 26 - 28 26 – 32(Begin with 29 – 32) Dose Groups 15 min; 30 min; 45 min( 25, 50, 75 TPL mg/kg)(8 active, 8 control per group)Single dose 60 min; 90 min (100 and 150 TPL mg/kg)(8 active, 8 control

  33. Slide 33: AEROSURF Phase 2 Program Update Investor Conference Call

    AEROSURF® Phase 2 Program UpdateInvestor Conference CallNovember 12, 2015

Discovery Laboratories — Corporate Update (November 2015) on 6ix